Clinical Trials Sponsored by Purdue Pharma LP

Total 95 results

Purdue Pharma LP

Terminated

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

Osteoarthritis Pain of the Knee

United States
Purdue Pharma LP

Withdrawn

Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

Other Acute Postoperative Pain | Prolonged Endotracheal Intubation
Purdue Pharma LP

Completed

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.

Back Pain

United States
Purdue Pharma LP

Completed

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

Chronic Pain | Osteoarthritis of the Knee

United States
Purdue Pharma LP

Terminated

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

Osteoarthritis

United States
Purdue Pharma LP

Completed

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Healthy Volunteers

United States
Purdue Pharma LP

Terminated

Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.

Osteoarthritis

United States
Purdue Pharma LP

Terminated

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Back Pain Lower Back Chronic

United States
Purdue Pharma LP

Completed

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Osteoarthritis

United States
Purdue Pharma LP

Completed

To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy

United States
Purdue Pharma LP

Completed

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy

United States
Purdue Pharma LP

Completed

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy Volunteers

United States
Purdue Pharma LP

Terminated

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

Chronic Non-Malignant Pain

United States
Purdue Pharma LP

Completed

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

Osteoarthritis

United States
Purdue Pharma LP

Terminated

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

Attention Deficit/Hyperactivity Disorder

United States
Purdue Pharma LP

Withdrawn

Clinical Outcomes From Nalmefene (COINED)

Opioid Overdose
Purdue Pharma LP

Completed

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Pain

United States, Israel, Spain, United Kingdom, Greece, Hungary, New Zealand, Romania
Purdue Pharma LP

Completed

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

ECG Effects

United States
Purdue Pharma LP

Completed

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

Pain

United States
Purdue Pharma LP

Completed

Experimental Biomarker Study for Pain Thresholds

Pain

Denmark
Purdue Pharma LP

Completed

An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain (Palladone)

Postoperative Pain

United States
Purdue Pharma LP

Completed

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
Purdue Pharma LP

Completed

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

Healthy

United States
Purdue Pharma LP

Terminated

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

Postsurgical Pain Due to Third Molar Extraction

United States
Purdue Pharma LP

Completed

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

Pain | Osteoarthritis, Knee

United States
Purdue Pharma LP

Completed

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

Chronic Nonmalignant Pain

United States
Purdue Pharma LP

Terminated

Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement

Postoperative Pain

United States
Purdue Pharma LP

Completed

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

Osteoarthritis

United States
Purdue Pharma LP

Completed

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

Healthy

United States
Purdue Pharma LP

Completed

The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain. (BP96-0604)

Back Pain

United States
Purdue Pharma LP

Completed

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy Volunteers

United States
Purdue Pharma LP

Completed

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy

United States
Purdue Pharma LP

Terminated

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (RE-DAX)

Attention-Deficit/Hyperactivity Disorder

United States
Purdue Pharma LP

Completed

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

Chronic Nonmalignant and Nonneuropathic Pain

United States
Purdue Pharma LP

Completed

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

Chronic Low Back Pain

United States
Purdue Pharma LP

Withdrawn

Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children

Pain
Purdue Pharma LP

Completed

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

Healthy

United States
Purdue Pharma LP

Completed

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

Pain

United States, Israel
Purdue Pharma LP

Completed

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Low Back Pain

United States, Poland, Czech Republic, Italy
Purdue Pharma LP

Completed

Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole

Healthy

United States
Purdue Pharma LP

Completed

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

Pain | Postherpetic Neuralgia

United States
Purdue Pharma LP

Completed

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

Opioid Analgesia

United States, Australia, Finland, New Zealand
Purdue Pharma LP

Terminated

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

Osteoarthritis

United States
Purdue Pharma LP

Terminated

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

Back Pain Lower Back Chronic

United States
Purdue Pharma LP

Terminated

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

Osteoarthritis

United States
Purdue Pharma LP

Completed

Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain

Osteoarthritis

United States
Purdue Pharma LP

Completed

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

Healthy

United States
Purdue Pharma LP

Completed

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Healthy Volunteers

United States

3

Subscribe